Equities

Bioxytran Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
BIXT:QBB

Bioxytran Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.0486
  • Today's Change0.000 / -0.91%
  • Shares traded48.00k
  • 1 Year change-40.06%
  • Beta2.1496
Data delayed at least 15 minutes, as of Feb 13 2026 20:46 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Bioxytran, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development, manufacture, and commercialization of therapeutic drugs designed to address hypoxia in humans. The Company's lead drug candidate, code named BXT-25, is an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer with intended applications, which includes the treatment of hypoxic conditions in the brain resulting from stroke. The Company, through its subsidiary, Pharmalectin Inc., is focused on the development, manufacturing, and commercialization of therapeutic drugs designed to address viral diseases in humans. Pharmalectin Inc. has developed a method designed to reduce the viral load and modulate the immune system using a galectin inhibitor. Its lead drug candidate, named ProLectin-Rx, is a complex polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin.

  • Revenue in USD (TTM)0.00
  • Net income in USD-2.11m
  • Incorporated2008
  • Employees2.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Cannabis Bioscience Internatnl Hlgs Inc148.34k-555.16k4.65m2.00------31.35-0.00006-0.000060.00001-0.00014.55--11.3574,170.00-1,702.42-652.66----73.1187.76-374.25-177.59---4.30----21.770.866215.74------
Genprex Inc0.00-17.05m4.68m15.00--2.64-----52.85-52.850.000.76460.00----0.00-448.99-100.44-1,253.41-109.71------------0.00------30.69------
Decoy Therapeutics Inc0.00-5.00m4.72m2.00--0.1643-----39.19-39.190.004.500.00----0.00-100.54-73.17-139.55-84.56-------987.44----0.00------55.55------
Bio Green Med Solution Inc81.00k-6.97m4.81m12.00--0.4835--59.32-80.13-80.130.07752.030.012--0.0821---80.35-65.34-175.85-83.8520.99---6,714.82-17,774.735.07-241.390.00---89.76--50.73------
Bioxytran Inc0.00-2.11m4.81m2.00---------0.0235-0.02350.00-0.03260.00-------1,340.44-1,468.56---------------1.99--------47.08------
Cyclerion Therapeutics Inc2.86m-2.20m4.91m1.00--0.4843--1.72-0.7587-0.75871.002.580.2957--39.652,855,000.00-22.77-53.70-24.80-63.57-----77.02-1,913.83----0.00-----15.0075.72------
Aspire Biopharma Holdings Inc1.94k-28.70m4.95m--------2,551.26-65.96-65.960.0022-9.260.0004-------633.21------45.36---1,479,598.00--0.1708-6.20---------380.85------
Weed Inc0.00-755.25k4.96m2.00---------0.0058-0.00580.00-0.00380.00----0.00-133.78-117.17---371.94-----------22.55---------1,518.25------
Silexion Therapeutics Corp0.00-9.25m4.97m11.00--0.7125-----25.21-25.210.002.230.00----0.00-125.80---221.96-------------84.500.1808-------223.39------
Xenetic Biosciences Inc2.86m-3.16m4.98m2.00--0.8478--1.74-2.05-2.051.852.570.436----1,429,470.00-48.14-42.99-57.42-46.44-----110.40-373.71----0.00---1.56171.114.22------
Acurx Pharmaceuticals Inc0.00-9.17m5.02m4.00--0.9751-----8.54-8.540.002.020.00----0.00-151.72-158.12-291.07-208.61------------0.00------3.26------
Processa Pharmaceuticals Inc0.00-12.93m5.03m10.00--0.8047-----35.00-35.000.002.760.00----0.00-206.50-104.23-270.68-112.35------------0.00-------6.55------
BioNexus Gene Lab Corp9.47m-2.30m5.06m30.00--0.5641--0.5345-1.28-1.285.273.791.026.736.42---24.68-6.00-27.80-7.7514.7714.31-24.27-4.986.81-1,354.050.00---2.66137.0939.20--77.67--
VivoSim Labs Inc140.00k-1.98m5.22m5.00--0.7383--37.26-0.1898-0.18980.0682.710.017--4.5910,769.23-24.12-51.63-34.26-56.4798.57---1,416.43-2,952.99----0.00--32.11-42.0183.04------
Bullfrog AI Holdings Inc116.67k-6.76m5.25m9.00--2.47--45.01-0.6936-0.69360.01190.18660.0319----12,963.33-184.34---233.50--18.76---5,770.66------0.0278---100.00---31.42------
MetaVia Inc0.00-16.22m5.26m9.00--0.5703-----13.88-13.880.002.880.00----0.00-87.87-99.54-167.49-140.07------------0.00-------121.27---48.18--
Data as of Feb 13 2026. Currency figures normalised to Bioxytran Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.